Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for people with multidrug-resistant virus.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for those with multidrug-resistant virus.
Long-awaited results from a Phase II study of ibalizumab, an antibody-based therapy in early stage development for several years
Ironically, the success of today’s antiretroviral treatments has hindered the development of new options for longtime survivors with drug...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.